Oppenheimer analyst Andreas Argyrides maintains $Sarepta Therapeutics (SRPT.US)$ with a buy rating, and maintains the target price at $215.
According to TipRanks data, the analyst has a success rate of 46.2% and a total average return of 13.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Sarepta Therapeutics (SRPT.US)$'s main analysts recently are as follows:
Following the company's announcement of a licensing agreement with another entity involving multiple programs, an analyst remains optimistic about the company's major product launch. The transaction is believed to enhance the company's pipeline, potentially adding new revenue streams beyond its primary franchise. This development is also seen as a strategic move to diversify the company's offerings and address investor concerns about overreliance on single-treatment gene therapies.
The collaboration between Sarepta and Arrowhead introduces a robust platform diversification and underscores a substantial long-term investment in chronic strategies targeting rare diseases. Additionally, this partnership broadens therapeutic coverage, with clinical programs extending across muscle, central nervous system, and pulmonary areas. The strategic alignment leverages Sarepta's proficiency in rare genetic medicine, and the accompanying share buyback initiative signals a positive outlook on near-term revenue projections.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
